Aphton (NASDAQ:APHT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Aphton Charts. Click Here for more Aphton Charts.](/p.php?pid=staticchart&s=N%5EAPHT&p=8&t=15)
Aphton Corporation (NASDAQ:APHT) today announced that
the company will present at the annual BIO 2005 Meeting in
Philadelphia, PA on Tuesday, June 21st at 11:15 AM EDT. Patrick
Mooney, M.D., Chairman and Chief Executive Officer will provide an
overview of the Company's pipeline and development programs and an
update on corporate strategies.
Strategic Pipeline
Aphton continues to focus its efforts on broadening and making
progress in its research and development pipeline. An important
element of this strategy is the addition of Igeneon's products,
IGN101, a cancer vaccine designed to induce an immune response against
EpCAM positive tumor cells, and IGN311, a fully humanized antibody
against the Lewis Y antigen. IGN101 is currently the subject of a
randomized, placebo controlled clinical trial in patients with
non-small cell lung cancer. This study has recently concluded
enrollment with more than 760 patients. Aphton also has a diverse
pipeline of pre-clinical and clinical products including active and
passive immunotherapies. Aphton believes that immunotherapies may have
certain advantages over other targeted therapies by including
specificity that may lead to better efficacy and decreased toxicities
for patients.
About Aphton
Aphton Corporation, headquartered in Philadelphia, PA, is a
clinical stage biopharmaceutical company focused on developing
targeted immunotherapies for cancer. Aphton's products seek to empower
the body's own immune system to fight disease. Through the acquisition
of Igeneon AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune response against
EpCAM positive tumor cells, and IGN311, a fully humanized antibody
against the Lewis Y antigen. Aphton is currently seeking partners that
will support the further development of Insegia (G17DT immunogen), its
immunogen targeting the hormone gastrin. Aphton has strategic
alliances with sanofi-aventis for the development and
commercialization of Insegia related to cancers of the
gastrointestinal system and other cancers in North America and Europe;
Daiichi Pure Chemicals for the development, manufacturing and
commercialization of gastrin-related diagnostic kits; and Xoma for
treating gastrointestinal and other gastrin-sensitive cancers using
anti-gastrin monoclonal and other antibodies. For more information
about Aphton or its programs please visit Aphton's website at
http://www.aphton.com.
Safe Harbor
This press release includes forward-looking statements, including
statements about: (1) Aphton's belief regarding the strength of
Igeneon's product portfolio and such portfolio's ability to complement
Aphton's product portfolio; (2) Aphton's intent to broaden and
progress its research and development pipeline; (3) Aphton's belief
that immunotherapies have certain advantages over targeted therapies;
(4) Aphton's expectation regarding the purpose and effectiveness of
IGN101 and IGN311; and (5) Aphton's ability to find a viable partner
to financially support the further development of Insegia. These
forward-looking statements may be affected by the risks and
uncertainties inherent in the drug development process and in Aphton's
business. This information is qualified in its entirety by cautionary
statements and risk factor disclosure contained in Aphton's Securities
and Exchange Commission filings, including Aphton's report on Form
10-K filed with the Commission on March 16, 2005. Aphton wishes to
caution readers that certain important factors may have affected and
could in the future affect Aphton's beliefs and expectations and could
cause the actual results to differ materially from those expressed in
any forward-looking statement made by or on behalf of Aphton. These
risk factors include, but are not limited to: (1) Aphton's ability to
fund the further development of its research and development; (2)
Aphton's ability to successfully identify and consummate opportunities
to broaden and progress its research and development pipeline; (3)
scientific developments regarding immunotherapies; (4) Aphton's
ability to successfully integrate Igeneon's operations and product
portfolio with Aphton's operations and product portfolio; and (5) the
actual design, results and timing of preclinical and clinical studies
for both companies' products and product candidates including, without
limitation the IGN 101 clinical trial referred to herein.